Business
Novartis Posts Strong Q1 Results, Lifts Full-Year Outlook Amid Surging Drug Sales
Swiss pharmaceutical giant Novartis reported stronger-than-expected earnings for the first quarter of 2025, buoyed by robust sales of key medicines and rising global demand. The company also raised its full-year guidance, signaling continued confidence in its product pipeline and market performance.
In the three months ending March 31, Novartis reported net sales of $13.2 billion, a 15% increase on a constant currency basis. The figure surpassed analyst expectations, which were estimated at $13.12 billion. Core operating income rose 23% to $5.6 billion, while core net income jumped 22% to $4.5 billion.
Following the strong quarterly performance, Novartis updated its full-year forecast. The company now expects sales to grow by high-single digits and core operating income to increase by low double-digits, narrowing and improving on its previous guidance issued in January.
Sales growth was largely driven by a strong performance across several flagship therapies. Breast cancer drug Kisqali recorded a 56% surge in revenue, reaching $956 million. Entresto, a treatment for heart failure, rose 22% to approximately $2.3 billion, while arthritis medication Cosentyx saw an 18% increase, bringing in around $1.5 billion.
Chief Executive Vas Narasimhan also highlighted progress on the innovation front, citing regulatory approvals for several new drugs. These include Pluvicto for prostate cancer in a pre-taxane setting, Vanrafia for IgA nephropathy, and Fabhalta for C3 glomerulopathy (C3G). “We remain focused on advancing our leading pipeline and confident in achieving our growth outlook,” Narasimhan stated in the earnings release.
The company is also navigating shifting regulatory and trade dynamics in the United States. A recent White House-initiated national security review of the pharmaceutical sector has raised questions about potential tariffs. While pharmaceuticals are currently exempt from proposed “reciprocal” tariffs, former President Donald Trump has floated a 25% import levy on medicines.
In response, Novartis recently announced a $23 billion investment plan in the U.S. over the next five years. The initiative includes the construction and expansion of 10 manufacturing facilities, with the goal of ensuring all medications for U.S. patients are produced domestically.
Novartis’s performance and expansion plans underscore the company’s strategic focus on growth through innovation and localized production amid global uncertainty.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
